07:30 AM EDT, 05/23/2025 (MT Newswires) -- Oncolytics Biotech ( ONCY ) on Friday said new data from the Phase I/II GOBLET clinical trial will be presented at a poster presentation at the American Society of Clinical Oncology (ASCO) meeting.

The presentation highlights pelareorep's mechanism of action in pancreatic ductal adenocarcinoma (PDAC), and offers new insights into how this immunotherapy stimulates multiple arms of the immune system and primes tumors for treatment.

"For the first time, we're able to map the cascade of immune responses stimulated by pelareorep," said Chief Medical Officer Thomas Heineman.

The findings deepen Oncolytics' understanding of pelareorep's ability to convert immunologically cold tumors into immunologically active ones that may benefit from pelareorep-based combination therapy, he added.